NasdaqGS:ZYMEBiotechs
How FDA Approval of Zanidatamab in HER2 Biliary Cancer Will Impact Zymeworks (ZYME) Investors
Zymeworks recently secured FDA approval for its internally developed therapy zanidatamab to treat HER2-positive biliary tract cancer, marking a key regulatory milestone for the company’s oncology portfolio.
This approval reinforces Zymeworks’ ability to convert its antibody engineering platforms into commercial-stage assets, an important proof point for its partnership- and royalty-focused business model.
We’ll now explore how FDA approval for zanidatamab in HER2-positive biliary tract...